Metraipolis › archive › dc_bf753ae6b69c
Tocilizumab and rituximab for systemic sclerosis interstitial lung disease: a real-world cohort analysis — Europe PMC PMID:39752322
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/39752322
- DOI
- 10.1093/rheumatology/keaf006
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-08T02:33:46.984Z
- SHA-256 of the archived text
3f5e6980d67cf27e680dd65b858b31272fcb0610b60687b0afc431ee56bc3cf1- Stable URL of this page
https://metraipolis.com/documento/dc_bf753ae6b69c
How to cite
Tocilizumab and rituximab for systemic sclerosis interstitial lung disease: a real-world cohort analysis — Europe PMC PMID:39752322 — Europe PMC (en), https://europepmc.org/article/MED/39752322 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_bf753ae6b69c (Metraipolis archive dc_bf753ae6b69c, sha256 3f5e6980d67cf27e680dd65b858b31272fcb0610b60687b0afc431ee56bc3cf1)
BibTeX
@misc{dcbf753ae6b69c,
title = {Tocilizumab and rituximab for systemic sclerosis interstitial lung disease: a real-world cohort analysis — Europe PMC PMID:39752322},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/39752322},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_bf753ae6b69c; sha256 3f5e6980d67cf27e680dd65b858b31272fcb0610b60687b0afc431ee56bc3cf1},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/39752322. Agents can read the archived copy with the MCP tool read_document.